The enemy of Gilead is coming! Iberville C cocktail viekira Pak approved by FDA

Source: Biovalley 2014-12-22 date, Ai Bowei (AbbVie) full oral hepatitis C cocktail Viekira Pak has been approved by the FDA!!! The listing of viekira Pak also marks the collapse of Gilead's dominant position in the field of hepatitis C treatment The industry forecasts that the annual peak sales of viekira Pak will reach US $3 billion However, harvoni's once-a-day advantage will help Gilead continue to dominate the hepatitis C market Viekira Pak is an all oral interferon free hepatitis C cocktail therapy, which is composed of fixed doses of ombitasvir / paritaprevir / ritonavir (25mg / 150mg / 100mg, once a day) and dasabuvir (250mg, twice a day) According to the prescription information of viekira Pak, the recommended dosage of the treatment scheme is: two fixed dose combinations (ombitasvir / paritaprevir / ritonavir, 12.5mg/75mg/50mg, taken at breakfast) and two dasabuvir (250mg, taken at breakfast and dinner respectively) every day The approval of viekira is based on the clinical data of the phase III project of the drug, which consists of six phase III studies in which the 12 week treatment regimen of viekira has achieved an impressive cure rate (svr12), up to 99% in some hepatitis C groups, including the most difficult genotype 1 hepatitis C group Analysts expect the annual peak sales of viekira to exceed $3 billion, but the annual peak sales of Geely's hepatitis C cocktail harvoni is as high as $12 billion In addition, although the efficacy of the two cocktails is similar, only one tablet per day is needed for harvoni of Gilead, and at least four tablets per day are needed for iberville's viekira Pak cocktail program, which may affect the prescription rate of viekira Pak But Alberto can balance that in terms of pricing Harvoni's 12 week treatment program costs $94500, a price that has been complained and protested by taxpayers around the world This situation gives Alberto an opportunity to undercut Gilead's market share by reducing prices At present, Aberdeen has not disclosed the price of viekira Pak, but said that the 12 week plan of viekira Pak may be priced at $83319, slightly lower than the star drug of Geely's hepatitis C sovaldi Last year, Gilead monopolized the headlines of various websites with the star drug of hepatitis C, sovaldi The 12 week plan of the drug was priced at $84000, and the 12 week plan of all oral cocktail harvoni was priced at $94500 However, some patients may only need to be cured in 8 weeks, so the cost of treatment can be reduced to $63000 A spokesman for Aberdeen said the company had considered many factors in pricing viekira Pak, including cost benefits and short-term and long-term costs It is not immediately clear what impact the pricing will have on the sales of Gilead harvoni However, viekira Pak needs to take 4 tablets a day, and Gilead harvoni only needs to take 1 tablet a day Therefore, it is widely expected that the advantages of harvoni will help Gilead continue to dominate the hepatitis C market However, no matter which company wins, the launch of the second new generation of hepatitis C cocktail is good news for 3.2 million hepatitis C patients in the United States Gilead launched the star drug sovaldi of hepatitis C since the end of 2013, which redefined the clinical treatment standard of hepatitis C and opened a new era of all oral care Edward Cox, director of FDA's office of antimicrobial products, said in a statement that the new generation of hepatitis C cocktail therapy is changing the clinical treatment mode of hepatitis C compared with the previous hepatitis C treatment scheme based on interferon injection, the new generation of all oral cocktail has a very high viral cure rate and better safety